We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genovis AB (GENO) NPV

Sell:28.95 SEK Buy:29.15 SEK Change: 0.65 SEK (2.18%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:28.95 SEK
Buy:29.15 SEK
Change: 0.65 SEK (2.18%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:28.95 SEK
Buy:29.15 SEK
Change: 0.65 SEK (2.18%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

Contact details

Medicon Village, Scheelevagen 2
223 63
+46 (46) 101230

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
1.95 billion SEK
Shares in issue:
66.26 million
Life Sciences Tools & Services
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Fredrik Olsson
    Chief Executive Officer
  • Magnus Langberg
    Chief Financial Officer
  • Rikke Rytter
    Vice President - Sales and Marketing
  • Stephan Bjork
    Vice President - Production
  • Helen Nyhlen
    Vice President - Quality Assurance
  • Rolf Lood
    Vice President - Research and Development
  • Susanne Ahlberg
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.